Compare VBNK & IRWD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | VBNK | IRWD |
|---|---|---|
| Founded | 1980 | 1998 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Commercial Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 606.0M | 663.6M |
| IPO Year | 2016 | 2009 |
| Metric | VBNK | IRWD |
|---|---|---|
| Price | $17.16 | $3.58 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 2 | 3 |
| Target Price | ★ $13.00 | $7.67 |
| AVG Volume (30 Days) | 71.5K | ★ 2.2M |
| Earning Date | 06-03-2026 | 05-11-2026 |
| Dividend Yield | ★ 0.41% | N/A |
| EPS Growth | N/A | ★ 1400.00 |
| EPS | N/A | ★ 0.24 |
| Revenue | N/A | ★ $298,276,000.00 |
| Revenue This Year | $30.02 | $57.95 |
| Revenue Next Year | $27.30 | $4.39 |
| P/E Ratio | $25.91 | ★ $15.23 |
| Revenue Growth | N/A | ★ 8.88 |
| 52 Week Low | $10.10 | $0.55 |
| 52 Week High | $19.02 | $5.78 |
| Indicator | VBNK | IRWD |
|---|---|---|
| Relative Strength Index (RSI) | 47.46 | 39.56 |
| Support Level | $15.74 | $3.07 |
| Resistance Level | $17.17 | $3.92 |
| Average True Range (ATR) | 0.51 | 0.33 |
| MACD | -0.22 | -0.11 |
| Stochastic Oscillator | 5.76 | 7.45 |
VersaBank is a Schedule I Canadian bank that provides mainly commercial lending and banking services to select niche markets in Canada and the United States. Its products and services include credit assets, deposits, and cybersecurity services through its wholly owned subsidiary. The bank operates through four segments: Digital Banking Canada and Digital Banking USA, both using a business-to-business model with proprietary financial technology to serve underserved markets; DRTC, which provides cybersecurity services and banking and financial technology development; and Digital Meteor, which owns proprietary technology supporting next-generation digital assets, including Real Bank Deposit Tokens (RBDTs). The majority of revenue comes from Digital Banking.
Ironwood Pharmaceuticals Inc is a biotechnology company developing and commercializing life-changing therapies for people living with gastrointestinal, or GI, and rare diseases. It is focused on the development and commercialization of inventive product opportunities in areas of unmet need, leveraging its demonstrated expertise and capabilities in GI and rare diseases. LINZESS is its commercial product. LINZESS is also available for the treatment of adults with IBS-C or CIC in Mexico, adults with IBS-C or chronic constipation in Japan, and adults with IBS-C in China. Linaclotide is available under the trademarked name CONSTELLA for the treatment of adults with IBS-C or CIC and pediatric patients ages 6-17 years old with FC in Canada, and to adults with IBS-C in certain European countries.